JP2007504112A5 - - Google Patents

Download PDF

Info

Publication number
JP2007504112A5
JP2007504112A5 JP2006524340A JP2006524340A JP2007504112A5 JP 2007504112 A5 JP2007504112 A5 JP 2007504112A5 JP 2006524340 A JP2006524340 A JP 2006524340A JP 2006524340 A JP2006524340 A JP 2006524340A JP 2007504112 A5 JP2007504112 A5 JP 2007504112A5
Authority
JP
Japan
Prior art keywords
hbsag
composition
composition according
hbv
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006524340A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007504112A (ja
JP4740133B2 (ja
Filing date
Publication date
Priority claimed from DE10339927A external-priority patent/DE10339927A1/de
Application filed filed Critical
Publication of JP2007504112A publication Critical patent/JP2007504112A/ja
Publication of JP2007504112A5 publication Critical patent/JP2007504112A5/ja
Application granted granted Critical
Publication of JP4740133B2 publication Critical patent/JP4740133B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006524340A 2003-08-29 2004-08-27 Hbv感染症およびhbv介在性疾患の予防/治療用組成物 Expired - Fee Related JP4740133B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10339927.5 2003-08-29
DE10339927A DE10339927A1 (de) 2003-08-29 2003-08-29 Zusammensetzung zur Prophylaxe/Therapie von HBV-Infektionen und HBV-vermittelten Erkrankungen
PCT/EP2004/009590 WO2005023297A1 (de) 2003-08-29 2004-08-27 Zusammensetzung zur prophylaxe/therapie von hbv-infektionen und hbv-vermittelten erkrankungen

Publications (3)

Publication Number Publication Date
JP2007504112A JP2007504112A (ja) 2007-03-01
JP2007504112A5 true JP2007504112A5 (enExample) 2010-12-16
JP4740133B2 JP4740133B2 (ja) 2011-08-03

Family

ID=34202216

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006524340A Expired - Fee Related JP4740133B2 (ja) 2003-08-29 2004-08-27 Hbv感染症およびhbv介在性疾患の予防/治療用組成物

Country Status (11)

Country Link
US (2) US20060233832A1 (enExample)
EP (1) EP1660125B1 (enExample)
JP (1) JP4740133B2 (enExample)
KR (2) KR20120026138A (enExample)
CN (1) CN1874787B (enExample)
AU (1) AU2004269882B2 (enExample)
BR (1) BRPI0414026A (enExample)
CA (1) CA2535734A1 (enExample)
DE (1) DE10339927A1 (enExample)
ES (1) ES2541123T3 (enExample)
WO (1) WO2005023297A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1764369A1 (de) 2005-09-16 2007-03-21 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Hbv 백신 및 그의 제조 방법
US9052304B2 (en) 2009-03-13 2015-06-09 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
US10076570B2 (en) * 2009-08-07 2018-09-18 Transgene S.A. Composition for treating HBV infection
CA2770075C (en) * 2009-08-07 2021-08-24 Perrine Martin Composition for treating hbv infection
US9238679B2 (en) * 2011-02-11 2016-01-19 The Trustees Of The University Of Pennslyvania Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
PE20140844A1 (es) 2011-02-12 2014-07-14 Globeimmune Inc Terapeuticos a base de levadura para infeccion de la hepatitis b cronica
SI3505528T1 (sl) 2011-04-21 2021-04-30 Glaxo Group Limited Modulacija izražanja virusa hepatitisa B (HBV)
EP2629096A1 (en) * 2012-02-20 2013-08-21 Roche Diagniostics GmbH HBV immunocomplexes for response prediction and therapy monitoring of chronic HBV patients
KR101646830B1 (ko) * 2013-05-31 2016-08-08 (주)셀트리온 B형 간염 바이러스를 중화시킬 수 있는 결합 분자
RU2733496C2 (ru) * 2015-03-16 2020-10-02 Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) Триспецифические связывающие молекулы для лечения вирусной инфекции гепатита в и связанных состояний
CN113058033B (zh) * 2019-12-16 2024-07-09 远大赛威信生命科学(南京)有限公司 一种用于预防和治疗乙型肝炎的药物组合物及其用途
EP4471055A4 (en) * 2022-01-25 2025-12-31 Univ Xiamen Epitope peptide and antibodies for treating HBV infection and associated diseases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196194A (en) * 1979-05-24 1993-03-23 The Regents Of The University Of California Vaccines containing Hepatitis B S-protein
EP0389983A3 (en) * 1989-03-31 1991-01-16 Abbott Laboratories Monoclonal antibodies to pres2 and pres1 polypeptides of the hepatitis b viral envelope
PT97632A (pt) * 1990-05-11 1992-03-31 Scripps Clinic Res Processo de obtencao de polipeptidos relacionados com a proteina do antigenio de superficie do virus da hepatite b e de vacinas que os contem
CA2041772A1 (en) * 1990-05-11 1991-11-12 Larry T. Mimms Monoclonal antibodies to pres2 and pres1 polypeptide of the hepatitis b viral envelope
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
IL101653A0 (en) * 1991-04-29 1992-12-30 Merck & Co Inc Multiple hepatitis b virus surface proteins which form particles
EP0533263A3 (en) * 1991-09-20 1994-06-08 Merck & Co Inc A multivalent hepatitis b virus vaccine
US6133244A (en) * 1993-10-22 2000-10-17 Institut Pasteur Method for immunization against hepatitis B
ZA973367B (en) * 1996-04-19 1997-11-18 Innogenetics Nv Method for typing and detecting HBV.
GB9608626D0 (en) * 1996-04-25 1996-07-03 Univ College Of London Hepatitis b monoclonal antibodies
EP1234040A2 (en) * 1999-12-03 2002-08-28 Innogenetics N.V. Hbv sequences
JP2001294599A (ja) * 2000-04-12 2001-10-23 Sekisui Chem Co Ltd 組み換えb型肝炎ウィルス表面抗原
US6858590B2 (en) * 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
RU2233672C1 (ru) * 2003-03-31 2004-08-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в и д, столбняка и дифтерии
RU2233673C1 (ru) * 2003-03-31 2004-08-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" Комбинированная вакцина для иммунопрофилактики коклюша, дифтерии, столбняка и вирусного гепатита в и д

Similar Documents

Publication Publication Date Title
Sominskaya et al. Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes
Glebe et al. The molecular virology of hepatitis B virus
Gerlich Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives
Valaydon et al. The virological aspects of hepatitis B
Michel et al. Hepatitis B vaccines: protective efficacy and therapeutic potential
Blum Hepatitis B virus: significance of naturally occurring mutants
Sureau et al. Production of infectious hepatitis delta virus in vitro and neutralization with antibodies directed against hepatitis B virus pre-S antigens
JP3049018B2 (ja) B型肝炎ワクチン
Sominskaya et al. A VLP library of C-terminally truncated Hepatitis B core proteins: correlation of RNA encapsidation with a Th1/Th2 switch in the immune responses of mice
CN1332749A (zh) 含有通过肽配体连接的多个免疫原性成分的hbv核心抗原颗粒
US20110263822A1 (en) Composition for the prophylaxis and treatment of hbv infections and hbv-mediated diseases
Tan et al. Phage display creates innovative applications to combat hepatitis B virus
Inan et al. Hepatitis B virus: Biology and life cycle
Sun et al. Hepatitis B virus pre‐S region: Clinical implications and applications
Wang et al. Detection of pre-S/S gene mutants in chronic hepatitis B carriers with concurrent hepatitis B surface antibody and hepatitis B surface antigen
Pantazica et al. Efficient cellular and humoral immune response and production of virus-neutralizing antibodies by the Hepatitis B Virus S/preS116-42 antigen
Wang et al. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice
Niedre‐Otomere et al. Recombinant Semliki Forest virus vectors encoding hepatitis B virus small surface and pre‐S1 antigens induce broadly reactive neutralizing antibodies
Yang et al. Expression and immunoactivity of chimeric particulate antigens of receptor binding site-core antigen of hepatitis B virus
JP2024105291A (ja) B型肝炎感染症を処置するための方法および組成物
Kniskern et al. Hepatitis B vaccines: blueprints for vaccines of the future
CN1108306A (zh) 羧端带有前表面抗原1决定簇的重组乙肝疫苗
Mancini-Bourgine et al. Impact of the immunogen nature on the immune response against the major HBV antigens in an HBsAg and HLA-humanized transgenic mouse model
CN110055228B (zh) 用于乙肝病毒感染的重组巨细胞病毒与应用
Liu et al. N-linked glycosylation at an appropriate position in the Pre-S2 domain is critical for cellular and humoral immunity against middle HBV surface antigen